ATF4 (Activating Transcription Factor 4) is the master transcriptional effector of the integrated stress response (ISR) — a conserved signaling network that allows eukaryotic cells to survive and adapt to nutrient deprivation, endoplasmic reticulum (ER) stress, viral infection, and oxidative stress. When stress signals converge on the phosphorylation of eIF2α at Ser51, the resulting translational reprogramming selectively upregulates ATF4 protein and triggers a broad gene expression program governing amino acid metabolism, redox homeostasis, autophagy, and cell fate decisions.
ATF4: Gene Structure, Protein, and Expression
The human ATF4 gene maps to chromosome 22q13 and encodes a 351 amino acid protein with a predicted molecular weight of approximately 38 kDa. It is also referred to as CREB-2, C/ATF, and TAXREB67 (Tax-responsive enhancer element-binding protein 67) in the literature; official HGNC ID: 786, Entrez Gene: 468, UniProtKB: P18848.
ATF4 belongs to the basic leucine zipper (bZIP) superfamily and contains two principal structural domains:
- N-terminal transactivation domain (TAD) — recruits co-activators and drives transcription of target genes
- C-terminal bZIP domain — mediates both sequence-specific DNA binding to CRE/CARE motifs and leucine-zipper-driven homodimerization and heterodimerization
ATF4 heterodimerizes with a range of bZIP partners including CHOP (DDIT3), ATF3, C/EBPβ, and NFE2L2/Nrf2, and the identity of the dimerization partner dictates which downstream gene programs are activated or repressed. The ATF4–CHOP heterodimer, for example, binds C/EBP-ATF response element (CARE) motifs (consensus: 5'-TGATGCAAT-3') and drives pro-apoptotic transcription under conditions of prolonged, unresolvable stress.
A defining feature of ATF4 biology is its post-transcriptional regulation by upstream open reading frames (uORFs) embedded in the 5' untranslated region of its mRNA. Under basal conditions, ribosomes translate uORF1 and then reinitiate at an inhibitory uORF2, preventing efficient translation of the main ORF. Under stress — when eIF2α-Ser51 is phosphorylated — the global reduction in ternary complex (eIF2–GTP–Met-tRNA) availability allows ribosomes that have translated uORF1 to bypass uORF2 and instead initiate at the ATF4 main ORF with markedly increased efficiency. This mechanistic framework, established by Harding et al. (2000) in Molecular Cell, explains how ATF4 protein levels can rise 10- to 20-fold in stressed cells even without changes in mRNA abundance (Harding et al., 2000 — DOI: 10.1016/s1097-2765(00)00108-8).
Important note for Western blot users: ATF4 migrates anomalously on SDS-PAGE, appearing at approximately 55 kDa despite its predicted molecular weight of 38 kDa. This well-documented anomalous migration results from the protein's amino acid composition, which leads to poor SDS binding. Researchers should set their WB detection window at ~50–60 kDa rather than 38 kDa to avoid missing the target band.
The Integrated Stress Response and ATF4 Induction
The integrated stress response (ISR) is defined by the convergence of four stress-sensing eIF2α kinases on a single phosphorylation site — Ser51 of the eIF2α subunit (EIF2S1). Each kinase senses a distinct category of cellular stress:
| Kinase (Gene) | Stress Sensed | Key ATF4 Target Genes Induced |
|---|---|---|
| HRI (EIF2AK1) | Heme deficiency, oxidative stress, heat shock | HMOX1, NRF2 targets, ASNS |
| PKR (EIF2AK2) | Double-stranded RNA (viral infection) | Antiviral ISGs, CHOP/DDIT3 |
| PERK (EIF2AK3) | Unfolded proteins in the ER (UPR) | CHOP/DDIT3, TRIB3, XBP1 |
| GCN2 (EIF2AK4) | Uncharged tRNAs (amino acid deprivation) | ASNS, SLC7A11, PHGDH, SESN2 |
All four kinases converge on eIF2α-Ser51 phosphorylation → ATF4 translational induction. The downstream gene programs activated by ATF4 vary by context but include:
- CHOP/DDIT3 — a pro-apoptotic bZIP factor; cooperates with ATF4 at CARE motifs to drive cell death under prolonged, unresolvable stress
- ASNS (asparagine synthetase) — amino acid biosynthesis reprogramming under GCN2/amino acid starvation
- TRIB3 (Tribbles 3) — a pseudo-kinase that provides negative feedback by inhibiting AKT and ATF4 itself
- SLC7A11 (xCT) — the cystine/glutamate antiporter; ATF4 transcriptionally upregulates xCT to maintain cystine import for glutathione synthesis, providing resistance to ferroptosis
- PHGDH — the rate-limiting enzyme of the serine synthesis pathway, linking ISR to one-carbon metabolism
A critical pharmacological tool in ISR research is ISRIB (integrated stress response inhibitor), which acts downstream of eIF2α phosphorylation by stabilizing the decameric form of the guanine nucleotide exchange factor eIF2B, thereby promoting ternary complex assembly even when eIF2α is phosphorylated. ISRIB does not block eIF2α phosphorylation itself — it reverses the downstream translational consequences, suppressing ATF4 induction. Sidrauski et al. (2013) demonstrated that ISRIB-treated mice show significant enhancement in spatial and fear-associated memory, revealing that the ISR tonically limits memory consolidation (Sidrauski et al., 2013 — DOI: 10.7554/eLife.00498). The ISR as a whole has been reviewed comprehensively by Pakos-Zebrucka et al. (2016) in EMBO Reports (Pakos-Zebrucka et al., 2016 — DOI: 10.15252/embr.201642195).
ATF4 in Disease: Cancer, Neurodegeneration, and Beyond
Because ATF4 sits at the nexus of stress adaptation and cell death, its dysregulation contributes to a wide spectrum of human diseases:
Cancer
Tumor cells face chronic nutrient limitation, hypoxia, and proteotoxic stress within the tumor microenvironment, and they frequently exploit the PERK-ATF4 axis as a survival mechanism. ATF4 drives expression of the serine synthesis enzymes PHGDH, PSAT1, and PSPH — fueling one-carbon metabolism and nucleotide synthesis in rapidly proliferating cells. In multiple myeloma, the PERK-ATF4-CHOP axis is mechanistically linked to bortezomib resistance: proteasome inhibition causes ER proteotoxic stress → PERK activation → ATF4 induction → adaptive transcriptional reprogramming that promotes survival. Targeting the ISR is therefore an active therapeutic strategy in several tumor types.
Neurodegeneration and Cognitive Function
Excessive eIF2α phosphorylation and resultant ATF4/ISR activation have been documented in Alzheimer's disease, prion disease, traumatic brain injury (TBI), and ALS. The observation that ISRIB reverses age-related cognitive decline and improves memory in aged mice (Science 2013; Sidrauski et al. eLife 2013) has generated enormous interest in ISR inhibition as a neurological therapeutic strategy. The ATF4 arm of the ISR also regulates synaptic plasticity through control of local dendritic protein synthesis.
Metabolic Disease and Bone Biology
PERK-ATF4 signaling is required for pancreatic beta cell survival under the high secretory demand of type 2 diabetes — PERK-knockout mice develop early-onset diabetes due to failure of beta cell ER homeostasis. In adipogenesis, ATF4 promotes lipogenesis and fat mass accumulation. In the skeleton, ATF4 is essential for osteoblast terminal differentiation: ATF4 cooperates with RUNX2 to transcriptionally activate osteocalcin (BGLAP), and ATF4-knockout mice develop severe low bone mass.
Ferroptosis
ATF4 transcriptionally upregulates SLC7A11 (xCT), which imports cystine in exchange for glutamate. Cystine is the rate-limiting precursor for glutathione (GSH) synthesis, which in turn provides reducing equivalents to GPX4 — the phospholipid hydroperoxide glutathione peroxidase that suppresses ferroptosis. Under moderate ISR activation, ATF4 therefore promotes ferroptosis resistance. Under severe or prolonged stress, however, ATF4-CHOP-driven pro-death programs can override this protective axis, ultimately committing the cell to apoptosis or ferroptotic death depending on context.
Detecting and Studying ATF4: Antibodies, Assays, and Reagents
Researchers studying the ATF4 pathway require reagents targeting ATF4 itself, its upstream regulators, and its downstream transcriptional targets. Key considerations for each workflow:
Western Blot for ATF4
As noted above, ATF4 runs anomalously at ~55 kDa on SDS-PAGE (predicted: 38 kDa). Validate antibody specificity with a positive control (cells treated with thapsigargin, tunicamycin, or sodium arsenite to activate the ISR). BioHippo stocks multiple validated ATF4 primary antibodies for WB, IHC, and IF, including:
- ATF4 Antibody (StressMarq, SMC-447D) — monoclonal, mouse IgG2a; validated in WB, IHC, IF; human and rat reactivity; available unconjugated and in multiple fluorescent conjugates (ATTO 390/488/594, APC, PE, PerCP, FITC, Biotin, HRP)
- Anti-ATF4 Polyclonal Antibody (BioHippo Inc, HB073014) — rabbit polyclonal; WB, IHC, ELISA; human, mouse, rat reactivity
- Anti-Human ATF4/CREB2 Antibody (N360A/24) — recombinant mouse monoclonal; WB and IHC
- Anti-ATF4 Antibody Picoband® (Boster Bio, A00371) — rabbit polyclonal; WB; human reactivity; available in 12 conjugate formats
Phospho-eIF2α (Ser51) as the Upstream ISR Readout
Phosphorylation of eIF2α at Ser51 is the canonical upstream biomarker of ISR activation and the mechanistic trigger for ATF4 induction. A phospho-specific antibody is essential for confirming ISR pathway engagement before attributing downstream effects to ATF4. BioHippo stocks the Recombinant Phospho-EIF2A (Ser51) Antibody (NSJ Bioreagents, R20320) — a rabbit recombinant monoclonal antibody validated for WB and IHC in human samples.
CHOP/DDIT3 as an ATF4 Downstream Target
CHOP (encoded by DDIT3) is the most widely used transcriptional marker of sustained ATF4 activity under pro-apoptotic stress. BioHippo offers the Anti-CHOP/GADD153/DDIT3 Polyclonal Antibody (HW574014) — rabbit polyclonal; validated for WB, IHC, and ELISA; human, mouse, rat reactivity.
Chromatin Immunoprecipitation (ChIP) for ATF4 Binding
ATF4 occupancy at CARE motifs (consensus: 5'-TGATGCAAT-3') in target gene promoters can be mapped by ChIP followed by qPCR or next-generation sequencing. Validated ChIP-grade ATF4 antibodies are essential — confirm ChIP suitability from the supplier's datasheet before purchase. Browse the full primary antibodies collection on BioHippo for ChIP-validated options.
ATF4 ELISA Kits
For quantitative measurement of ATF4 protein levels in cell lysates or tissue homogenates, BioHippo offers species-specific sandwich ELISA kits from ELK Biotechnology:
- Human ATF4 ELISA Kit (ELK1681) — detection range 0.16–10 ng/mL, sensitivity 0.056 ng/mL
- Mouse ATF4 ELISA Kit (ELK0365) — detection range 78.13–5000 pg/mL
- Rat ATF4 ELISA Kit (ELK7264) — detection range 78.13–5000 pg/mL
Also available: Recombinant Human ATF4 protein (Fine Test, P0583) for use as a standard or positive control in functional and binding assays.
Frequently Asked Questions About ATF4
What is ATF4?
ATF4 (Activating Transcription Factor 4, also known as CREB-2) is a basic leucine zipper (bZIP) transcription factor encoded by the ATF4 gene on chromosome 22q13 in humans. It is the master transcriptional effector of the Integrated Stress Response (ISR), a conserved signaling pathway in eukaryotic cells that is activated in response to diverse stresses including ER stress, amino acid deprivation, oxidative stress, and viral infection. ATF4 protein levels are controlled primarily at the translational level via upstream open reading frames (uORFs) in its mRNA, making it uniquely responsive to the reduction in ternary complex availability that accompanies eIF2α-Ser51 phosphorylation.
What activates the ATF4 pathway?
ATF4 is activated whenever any of the four ISR kinases — HRI (EIF2AK1), PKR (EIF2AK2), PERK (EIF2AK3), or GCN2 (EIF2AK4) — phosphorylates eIF2α at Ser51. Each kinase responds to a distinct upstream signal: HRI to heme deficiency and oxidative stress; PKR to double-stranded RNA during viral infection; PERK to unfolded proteins accumulating in the ER; and GCN2 to uncharged tRNAs during amino acid starvation. Common laboratory stimuli used to activate ATF4 include thapsigargin (PERK/UPR), tunicamycin (PERK/UPR), sodium arsenite (HRI/oxidative stress), and leucine deprivation (GCN2).
What is the integrated stress response?
The integrated stress response (ISR) is a conserved eukaryotic signaling pathway in which phosphorylation of eIF2α at Ser51 — by one of four specialized kinases — simultaneously reduces global cap-dependent mRNA translation and selectively increases the translation of stress-responsive mRNAs, including ATF4. The ISR was named for its ability to integrate signals from multiple, otherwise disparate stress inputs into a unified downstream response. Under moderate stress, the ISR is a pro-survival, homeostatic program that promotes stress recovery; under severe or prolonged stress, ISR signaling (especially via ATF4-CHOP) drives apoptosis. The ISR is reviewed comprehensively in Pakos-Zebrucka et al. 2016 (EMBO Reports, DOI: 10.15252/embr.201642195).
What genes does ATF4 regulate?
ATF4 binds C/EBP-ATF Response Element (CARE) motifs in target gene promoters and regulates a broad transcriptional program. Key direct target genes include: CHOP/DDIT3 (pro-apoptotic under sustained stress), ASNS (asparagine synthetase — amino acid biosynthesis), TRIB3 (negative feedback regulator of ATF4 and AKT), SLC7A11 (xCT cystine transporter — links ISR to ferroptosis resistance), PHGDH and PSAT1 (serine synthesis pathway — fuels one-carbon metabolism), SESN2 (sestrin — antioxidant and mTORC1 inhibitor), and FGF21 (fibroblast growth factor 21 — metabolic hormone). The precise ATF4 target gene program is strongly context-dependent, shaped by the identity of its dimerization partner and the chromatin landscape of the stressed cell.
How is ATF4 related to cancer and neurodegeneration?
In cancer, ATF4 is frequently upregulated in solid tumors because it enables survival in the nutrient-poor, hypoxic tumor microenvironment and drives serine biosynthesis to fuel cancer cell proliferation. The PERK-ATF4 axis is also linked to resistance to proteasome inhibitors in multiple myeloma. In neurodegeneration, excessive and chronic ISR activation — with persistent ATF4 induction — suppresses the protein synthesis required for synaptic plasticity and memory consolidation, and has been documented in Alzheimer's disease, prion disease, and TBI. Pharmacological ISR inhibitors such as ISRIB, which reverse eIF2α-phosphorylation-dependent ATF4 induction by stabilizing eIF2B, have shown remarkable efficacy in mouse models of neurodegeneration and cognitive aging, validating the ISR-ATF4 axis as a tractable therapeutic target in both oncology and neurology.